期刊文献+

二次检索

题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到2,586篇文章
< 1 2 130 >
每页显示 20 50 100
Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis
1
作者 Yan-Chao Hu Xiang-Chun Ding +3 位作者 Hui-Juan Liu Wan-Long Ma Xue-Yan Feng Li-Na Ma 《World Journal of Gastroenterology》 SCIE CAS 2024年第11期1556-1571,共16页
BACKGROUND Hepatitis B cirrhosis(HBC)is a chronic disease characterized by irreversible diffuse liver damage and aggravated by intestinal microbial imbalance and metabolic dysfunction.Although the relationship between... BACKGROUND Hepatitis B cirrhosis(HBC)is a chronic disease characterized by irreversible diffuse liver damage and aggravated by intestinal microbial imbalance and metabolic dysfunction.Although the relationship between certain single probiotics and HBC has been explored,the impact of the complex ready-to-eat Lactobacillus paracasei N1115(LP N1115)supplement on patients with HBC has not been determined.AIM To compare the changes in the microbiota,inflammatory factor levels,and liver function before and after probiotic treatment in HBC patients.METHODS This study included 160 HBC patients diagnosed at the General Hospital of Ningxia Medical University between October 2018 and December 2020.Patients were randomly divided into an intervention group that received LP N1115 supplementation and routine treatment and a control group that received routine treatment only.Fecal samples were collected at the onset and conclusion of the 12-wk intervention period.The structure of the intestinal microbiota and the levels of serological indicators,such as liver function and inflammatory factors,were assessed.RESULTS Following LP N1115 intervention,the intestinal microbial diversity significantly increased in the intervention group(P<0.05),and the structure of the intestinal microbiota was characterized by an increase in the proportions of probiotic microbes and a reduction in harmful bacteria.Additionally,the intervention group demonstrated notable improvements in liver function indices and significantly lower levels of inflammatory factors(P<0.05).CONCLUSION LP N1115 is a promising treatment for ameliorating intestinal microbial imbalance in HBC patients by modulating the structure of the intestinal microbiota,improving liver function,and reducing inflammatory factor levels. 展开更多
关键词 hepatitis b cirrhosis N1115 ready-to-eat lactobacillus Inflammation liver function Lachnospiraceae incertae sedis Probiotic
下载PDF
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
2
作者 You-Wen Tan Jia-Min Wang Xing-Bei Zhou 《World Journal of Hepatology》 2023年第2期237-254,共18页
BACKGROUND Although many studies have investigated the impact of chronic hepatitis B virus(HBV)infection and nonalcoholic fatty liver disease(NAFLD)on liver disease,few have investigated the relationship between nonal... BACKGROUND Although many studies have investigated the impact of chronic hepatitis B virus(HBV)infection and nonalcoholic fatty liver disease(NAFLD)on liver disease,few have investigated the relationship between nonalcoholic steatohepatitis(NASH)defined by liver pathology and the prognosis of chronic HBV infection.Most patients were followed up for a short time.This study aimed to further explore the impact of NAFLD and the pathological changes confirmed by liver pathology in patients with chronic HBV infection.AIM To study the effect of NAFLD confirmed using liver pathology on the outcomes of long-term serious adverse events[cirrhosis,hepatocellular carcinoma(HCC),and death]in patients with chronic hepatitis B(CHB)virus infection.METHODS We enrolled patients with chronic hepatitis B virus(HBV)infection who underwent liver biopsy at the Third People’s Hospital of Zhenjaing Affiliated Jiangsu University between January 2005 and September 2020.Baseline clinical and pathological data on liver pathology and clinical data at the end of follow-up were collected.Propensity score matching(PSM)was used to balance baseline parameters,Kaplan-Meier(K-M)survival analysis was used to evaluate the risk of clinical events,and Cox regression was used to analyze the risk factors of events.RESULTS Overall,456 patients with chronic HBV infection were included in the study,of whom 152(33.3%)had histologically confirmed NAFLD.The median follow-up time of the entire cohort was 70.5 mo.Thirty-four patients developed cirrhosis,which was diagnosed using ultrasound during the follow-up period.K-M survival analysis showed that NAFLD was not significantly associated with the risk of cirrhosis(log-rank test,P>0.05).Patients with CHB with fibrosis at baseline were more prone to cirrhosis(log-rank test,P=0.046).After PSM,multivariate analysis showed that diabetes mellitus,ballooning deformation(BD),and platelet(PLT)were independent risk factors for cirrhosis diagnosed using ultrasound(P<0.05).A total of 10 patients(2.2%)developed HCC,and six of these patients were in the combined NAFLD group.K-M survival analysis showed that the cumulative risk of HCC in the NAFLD group was significantly higher(log-rank test,P<0.05).Hepatocyte ballooning,and severe liver fibrosis were also associated with an increased risk of HCC(log-rank test,all P<0.05).Cox multivariate analysis revealed that hepatocyte ballooning,liver fibrosis,and diabetes mellitus were independent risk factors for HCC.CONCLUSION There was no significant correlation between chronic HBV infection and the risk of cirrhosis in patients with NAFLD.Diabetes mellitus,BD,and PLT were independent risk factors for liver cirrhosis.Patients with chronic HBV infection and NASH have an increased risk of HCC.BD,liver fibrosis,and diabetes mellitus are independent risk factors for HCC. 展开更多
关键词 Nonalcoholic fatty liver disease STEATOhepatitis Chronic hepatitis b virus infection Hepatocellular carcinoma cirrhosis
下载PDF
Serum and ascites levels of macrophage migration inhibitory factor, TNF-α and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis 被引量:18
3
作者 Wei Zhang Bei Yue +1 位作者 Gui-Qiang Wang Shu-Lan Lu the Department of Infectious Dispeases, Ruijing Hospital, Shanghai Second Medical University, Shanghai 200025, China Department of Intectious Diseases, Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2002年第4期577-580,共4页
Objective: To study the potential role of macrophage migration inhibitory factor (MIF), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the development of chronic virus hepatitis B (CH) and hepatitis cir... Objective: To study the potential role of macrophage migration inhibitory factor (MIF), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the development of chronic virus hepatitis B (CH) and hepatitis cirrhosis (HC). Methods: The serum concentrations of MIF, TNF-α and IL-6 in 18 patients with chronic virus hepatitis B and in 14 patients with hepatitis cirrhosis without as- citic fluid, and the serum and ascites cytokine con- centrations in 22 HC patients with ascitic fluid were detected by enzyme linked immunity sorbed assay. Results: The cytokine concentrations of the patients were significantly higher than those of the controls. The serum levels of MIF, TNF-α and IL-6 of the 22 patients with ascitic fluid were higer than those of 14 HC patients without ascites. In the 18 patients with CH, the serum cytokine concentrations were the low- est. The serum cytokine concentrations of the 22 HC patients with ascites were significantly higher than those of the 14 HC patients without ascites (P< 0. 01). Their serum cytokine concentrations were sig- nificantly higher than those in the 18 patients with CH (P<0. 01). The concentration of IL-6 in ascites was the highest among all the groups. The serum le- vels of MIF, TNF-α and IL-6 are correlated with al- anine aminotransferase (ALT) in the patients with CH, but not in those with HC with or without asci- tes. Conclusions: These results indicated that MIF, TNF- α and IL-6 may participate in the pathological process of CH and cirrhosis, that IL-6 seems to play an important role in ascites formation, and that se- rum levels of MIF, TNF-α and IL-6 appear to reflect the severity of tissue injury in HBV disease. 展开更多
关键词 macrophage migration inhibitory factor tumor necrosis factor-α interleukin-6 chronic virus hepatitis b hepatitis cirrhosis ascites
下载PDF
Bacterial infection triggers and complicates acute-on-chronic liver failure in patients with hepatitis B virus-decompensated cirrhosis: A retrospective cohort study 被引量:19
4
作者 Zhu-Jun Cao Yu-Han Liu +13 位作者 Chuan-Wu Zhu Shan Yin Wei-Jing Wang Wei-Liang Tang Gang-De Zhao Yu-Min Xu Lu Chen Tian-Hui Zhou Ming-Hao Cai Hui Wang Wei Cai Shi-San Bao Hai Li Qing Xie 《World Journal of Gastroenterology》 SCIE CAS 2020年第6期645-656,共12页
BACKGROUND Reports on bacterial infection(BI)in decompensated cirrhosis(DC)is mainly from alcoholic cirrhosis.The role of BI as a trigger or complication of acute-onchronic liver failure(ACLF)in patients with hepatiti... BACKGROUND Reports on bacterial infection(BI)in decompensated cirrhosis(DC)is mainly from alcoholic cirrhosis.The role of BI as a trigger or complication of acute-onchronic liver failure(ACLF)in patients with hepatitis B virus decompensated cirrhosis(HBV-DC)remains to be investigated.AIM To investigate the impact of BI on the outcomes of the patients with HBV-DC admitted into the hospital with or without ACLF.METHODS This retrospective study included patients with HBV-DC admitted to two tertiary centers in China.In-hospital overall survival,90-d transplant-free survival,5-year post-discharge survival,and cumulative incidence of ACLF were evaluated.Risk factors for death were analyzed considering liver transplantation as a competing event.RESULTS A total of 1281 hospitalized HBV-DC patients were included;284 had ACLF at admission.The overall prevalence of BI was 28.1%.The patients with BI had a significantly lower in-hospital survival and transplant-free 90-d survival than those without,in both the patients admitted with and without ACLF.The presence of BI significantly increased the risk of developing ACLF[subdistribution hazard ratio(sHR)=2.52,95%CI:1.75-3.61,P<0.001]in the patients without ACLF.In the patients discharged alive,those who had an episode of BI had a significantly lower 5-year transplant-free survival.BI was an independent risk factor for death in the patients admitted without ACLF(sHR=3.28,95%CI:1.93-5.57),while in ACLF admissions,the presence of pneumonia,but not other type of BI,independently increased the risk of death(sHR=1.87,95%CI:1.24-2.82).CONCLUSION BI triggers ACLF in patients with HBV-DC and significantly impairs short-term survival.HBV-DC patients should be monitored carefully for the development of BI,especially pneumonia,to avoid an adverse outcome. 展开更多
关键词 hepatitis b virus cirrhosis DECOMPENSATION bacterial infection Acute-onchronic liver failure SURVIVAL
下载PDF
EXPRESSION OF INSULIN-LIKE GROWTH FACTOR Ⅱ(IGF-Ⅱ)IN HUMAN HEPATOCELLULAR CARCINOMA AND LIVER CIRRHOSIS:ITS RELATIONSHIP WITH HEPATITIS B VIRUS X PROTEIN EXPRESSION
5
作者 张劲风 苏勤 +1 位作者 贺晓慧 刘彦仿 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1996年第3期9-14,共6页
Sixty cases of hepatocellular carcinoma (HCC) and 47 cases of liver cirrhosis (LC) were examined with immunocytochemistry method using antibodies against IGF-II and HBxAg on formalin-fixed, paraffin-embedded tissue se... Sixty cases of hepatocellular carcinoma (HCC) and 47 cases of liver cirrhosis (LC) were examined with immunocytochemistry method using antibodies against IGF-II and HBxAg on formalin-fixed, paraffin-embedded tissue sections. 32 HCC and 37 LC were found to be positive to HBxAg, in which the positive rates of IGF-II were 100% (32/32) and 94.6% (35/37) respectively. 28 HCC and 10 LC were found to be HBxAg negative, IGF-II was positive in 23 HCC (83.1%) and 6 LC (60%). The positive expression rates of IGF-II in HBxAg positive tissues were significantly higher than those in HBxAg negative tissues (P<0.05). There were three types of distribution of IGF-II expression in HCC and LC: (1) perinucleus; (2) diffuse in cytoplasm; (3) inside nucleus. IGF-II was highly expressed in most of hyperplastic and neoplastic nodules hepatocytes and some of regeneration nodules. Small polygonal liver cells (SPLCs) were found in the liver tissues surrounding the tumor and cirrhosis and they were positive to both IGF-II and HBxAg. The positive rates of IGF-II in SPLC were 86.4% (38/44) in the HBxAg-positive tissues and 40.5%, (15/37) in the HBxAg-negative tissues. The above findings suggest that IGF-II plays an important role in abnormal proliferation of HCC and SPLC. The relation between IGF-II andHBxAg and the nature of SPLCs are also discussed. 展开更多
关键词 liver neoplasms liver cirrhosis Insulin-like growth factor II hepatitis b virus antigens Immuno-cytochemistry.
下载PDF
Hepatitis B cirrhosis combined with Budd-Chiari syndrome treated by liver transplantation:Case report and literature review
6
作者 Liang Xu Jian Xu +5 位作者 Hong-Tao Jiang Shan-Bin Zhang De-Sheng Li Hui-Ling Gan Hou-Qin Liu Fan-Jun Zeng 《Journal of Hainan Medical University》 2021年第2期58-60,共3页
Objective:To summarize and analyze the clinical treatment experience of hepatitis B cirrhosis combined with Budd-Chiari syndrome.Methods:Data was obtained from a patient who were diagnosed with hepatitis B cirrhosis c... Objective:To summarize and analyze the clinical treatment experience of hepatitis B cirrhosis combined with Budd-Chiari syndrome.Methods:Data was obtained from a patient who were diagnosed with hepatitis B cirrhosis combined with Budd-Chiari syndrome.We retrospectively analyzed the clinical character of the patient.Results:The patient was diagnosed with Budd-Chiari syndrome incidentally during operation.so the patient underwent orthotopic liver transplanation,in which the liver and retrohepatic vena cava were resected,and recovered uneventfully.Conclusion:Orthotopic liver transplantation is not only an ideal treatment but also improves the prognosis of patients for hepatitis B cirrhosis combined with Budd-Chiari syndrome. 展开更多
关键词 hepatitis b cirrhosis budd-Chiari syndrome Hepato-pulmonary syndrome liver transplantation
下载PDF
Influence of antiviral drugs combined with antioxidant therapy on liver injury and fibrosis process in patients with chronic hepatitis B cirrhosis
7
作者 Guo-Yun Wan Hui Liu 《Journal of Hainan Medical University》 2017年第11期39-42,共4页
Objective:To study the influence of antiviral drugs combined with antioxidant therapy on liver injury and fibrosis process in patients with chronic hepatitis B cirrhosis.Methods: A total of118 patients with chronic he... Objective:To study the influence of antiviral drugs combined with antioxidant therapy on liver injury and fibrosis process in patients with chronic hepatitis B cirrhosis.Methods: A total of118 patients with chronic hepatitis B cirrhosis who were treated in Dongying Hospital for Infectious Diseases between May 2013 and February 2016 were retrospectively analyzed and divided into the control group (n=60) who underwent routine antiviral therapy and the observation group (n=58) who underwent antiviral drugs combined with antioxidant therapy. Serum levels of oxidative stress indexes, liver function indexes and liver fibrosis indexes were compared between two groups of patients before and after treatment.Results:Before treatment, there were no significant differences in serum oxidative stress indexes, liver function indexes and liver fibrosis indexes between two groups of patients. 3 months after treatment, serum oxidative stress index SOD level in observation group was higher than that in control group while AOPPs level was lower than that in control group;serum liver function indexes AST, ALT and TBIL levels in observation group were lower than those in control group while ALB level was higher than that in control group;serum liver fibrosis indexes HA,Ⅳ-C, PCIII and LN levels in observation group were lower than those in control group.Conclusion:Antiviral drugs combined with antioxidant therapy can significantly reduce oxidative stress injury in patients with chronic hepatitis B cirrhosis so as to protect the liver function and inhibit the liver fibrosis process. 展开更多
关键词 CHRONIC hepatitis b cirrhosis ANTIVIRAL ANTIOXIDANT liver injury FIbROSIS
下载PDF
Clinical and Paraclinical Profiling of Patients with Viral Hepatitis B and C Attending Saint Camille Hospital in Ouagadougou (HOSCO)
8
作者 Théodora Mahoukèdè Zohoncon Denise P. Ilboudo +3 位作者 Lionel Dahourou Titeon Rose Clémence Ido Da Luc Zongo Jacques Simpore 《Journal of Biosciences and Medicines》 2023年第10期225-240,共16页
The present study aims to describe the clinical and paraclinical profile of patients infected by viral hepatitis B and C and follow-up. The clinical and paraclinical data used in this description are from patients inf... The present study aims to describe the clinical and paraclinical profile of patients infected by viral hepatitis B and C and follow-up. The clinical and paraclinical data used in this description are from patients infected by viral hepatitis B and C of the HOSCO Hepato-Gastroenterological Department from May 15, 2021 to July 23, 2021. The informed consent was provided to each patient included in this study. “Univariate analyses were evaluated using Pearson’s Chi2 test” using R software version 4.0.2. During the study period, we identified 149 patients with viral hepatitis B and/or C who met our inclusion criteria. The sex ratio was 0.83 at the rate of 68 men for 81 women with the average age at 37.17 years ± 12.21 years. The most represented age group was 30 - 44 years (49.7%). The most incriminated risk factors were medical care by injection (62.58%), excision (31.90%), blood transfusion (4.29%) and scarification (1.23%). HBV infection was the majority with a frequency of 95.97%. The HBV viral load was measured in 91.95% of patients, 77.18% of whom had a detectable DNA viral load ≤ 2000 IU/mL. The clinical and biological course was good in patients after therapeutic initiation. HBV-HCV-HIV co-infection was 0.67%. Abdominal ultrasound was normal in 87.92% of patients. Fibrosis was minimal and moderate in 58.39% and 19.46% of patients. Among patients, 52.35% were on Tenofovir therapy, 2.68% on Sofosbuvir/Velpatasvir, 0.67% on ARVs and 44.29% did not require treatment. Viral hepatitis B and C are common, and both affect sex. Thus, new screening strategies need to be implemented to improve the diagnosis of hepatitis B and C. Effective strategies against viral hepatitis B and C must be developed, subsequently. 展开更多
关键词 hepatitis b and C CO-INFECTION Primary liver Cancer (PLC) cirrhosis HOSCO
下载PDF
On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B 被引量:14
9
作者 Xiu-Juan Chang Chao Sun +17 位作者 Yan Chen Xiao-Dong Li Zu-Jiang Yu Zheng Dong Wen-Lin Bai Xiao-Dong Wang Zhi-Qin Li Da Chen Wen-Juan Du Hao Liao Qi-Yu Jiang Li-Jun Sun Yin-Yin Li Cui-Hong Zhang Dong-Ping Xu Yong-Ping Chen Qin Li Yong-Ping Yang 《World Journal of Gastroenterology》 SCIE CAS 2019年第32期4764-4778,共15页
BACKGROUND Non-invasive evaluation for liver fibrosis is clinically important,especially in patients with undetectable hepatitis B virus(HBV)DNA treated with nucleoside analogs.AIM To clarify the monitoring power of h... BACKGROUND Non-invasive evaluation for liver fibrosis is clinically important,especially in patients with undetectable hepatitis B virus(HBV)DNA treated with nucleoside analogs.AIM To clarify the monitoring power of hepatitis B core-related antigen(HBcrAg)for hepatic histologic changes in patients with chronic hepatitis B(CHB)treated with entecavir.METHODS This prospective multicenter study used multiple ordinal and multivariate logistics regression analysis to assess variables associated with Ishak fibrosis score and regression for fibrosis regression,respectively,in 403 CHB patients,including 374 with entecavir for 72 weeks(291 underwent paired liver biopsy)and 29 as controls.RESULTS Level of HBcrAg correlated negatively with liver fibrosis staging(γ=-0.357,P<0.001)in hepatitis B e antigen(HBeAg)-positive patients,and positively with liver fibrosis staging in HBeAg-negative patients.Higher HBcrAg concentration was associated with younger age,HBeAg positive status,high HBV DNA loads,high level of hepatitis B surface antigen(HBsAg)and higher necroinflammation,but not with HBV genotype.Serum concentration of HBcrAg,basal core promoter/precore(BCP/PC)mutant,quantitation of HBsAg(qHBsAg)and platelet counts were independently associated with Ishak fibrosis score on multiple ordinal regression.HBV DNA was undetectable in 88.37%of patients treated with entecavir at week 72,while their level of HBcrAg was still detectable.A greater reduction in post-treatment HBcrAg concentration was associated with the regression of hepatic fibrosis and histological improvement.HBcrAg concentration>6.33 log IU/mL at baseline and logarithmic reduction>1.03 log IU/mL at week 72 were associated with a higher chance of regression of liver fibrosis and histological improvement,respectively.CONCLUSION HBcrAg level is associated with liver fibrosis progression.HBcrAg is an excellent monitor of hepatic histological changes,especially in CHB patients treated with nucleoside analogs. 展开更多
关键词 hepatitis b core-related ANTIGEN liver fibrosis cirrhosis On-treatment monitoring
下载PDF
Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China 被引量:7
10
作者 Min-Jun Liao Jun Li +8 位作者 Wei Dang Dong-Bo Chen Wan-Ying Qin Pu Chen Bi-Geng Zhao Li-Ying Ren Ting-Feng Xu Hong-Song Chen Wei-Jia Liao 《World Journal of Gastroenterology》 SCIE CAS 2022年第27期3503-3513,共11页
BACKGROUND Noninvasive,practical,and convenient means of detection for the prediction of liver fibrosis and cirrhosis in China are greatly needed.AIM To develop a precise noninvasive test to stage liver fibrosis and c... BACKGROUND Noninvasive,practical,and convenient means of detection for the prediction of liver fibrosis and cirrhosis in China are greatly needed.AIM To develop a precise noninvasive test to stage liver fibrosis and cirrhosis.METHODS With liver biopsy as the gold standard,we established a new index,[alkaline phosphatase(U/L)+gamma-glutamyl transpeptidase(U/L)/platelet(109/L)(AGPR)],to predict liver fibrosis and cirrhosis.In addition,we compared the area under the receiver operating characteristic curve(AUROC)of AGPR,gammaglutamyl transpeptidase to platelet ratio,aspartate transaminase to platelet ratio index,and FIB-4 and evaluated the accuracy of these routine laboratory indices in predicting liver fibrosis and cirrhosis.RESULTS Correlation analysis revealed a significant positive correlation between AGPR and liver fibrosis stage(P<0.001).In the training cohort,the AUROC of AGPR was 0.83(95%CI:0.78-0.87)for predicting fibrosis(≥F2),0.84(95%CI:0.79-0.88)for predicting extensive fibrosis(≥F3),and 0.87(95%CI:0.83-0.91)for predicting cirrhosis(F4).In the validation cohort,the AUROCs of AGPR to predict≥F2,≥F3 and F4 were 0.83(95%CI:0.77-0.88),0.83(95%CI:0.77-0.89),and 0.84(95%CI:0.78-0.89),respectively.CONCLUSION The AGPR index should become a new,simple,accurate,and noninvasive marker to predict liver fibrosis and cirrhosis in chronic hepatitis B patients. 展开更多
关键词 liver FIbROSIS cirrhosis PREDICTION Novel noninvasive marker Chronic hepatitis b
下载PDF
Computed tomography perfusion in liver and spleen for hepatitis B virus-related portal hypertension:A correlation study with hepatic venous pressure gradient 被引量:4
11
作者 Lei Wang Yu Zhang +5 位作者 Yi-Fan Wu Zhen-Dong Yue Zhen-Hua Fan Chun-Yan Zhang Fu-Quan Liu Jian Dong 《World Journal of Gastroenterology》 SCIE CAS 2022年第42期6068-6077,共10页
BACKGROUND Hepatic venous pressure gradient(HVPG)is the gold standard for diagnosis of portal hypertension(PH).However,its use can be limited because it is an invasive procedure.Therefore,it is necessary to explore a ... BACKGROUND Hepatic venous pressure gradient(HVPG)is the gold standard for diagnosis of portal hypertension(PH).However,its use can be limited because it is an invasive procedure.Therefore,it is necessary to explore a non-invasive method to assess PH.AIM To investigate the correlation of computed tomography(CT)perfusion of the liver with HVPG and Child-Pugh score in hepatitis B virus(HBV)-related PH.METHODS Twenty-eight patients(4 female,24 male)with gastroesophageal variceal bleeding induced by HBV-related PH were recruited in our study.All patients received CT perfusion of the liver before transjugular intrahepatic portosystemic stent-shunt(TIPS)therapy.Quantitative parameters of CT perfusion of the liver,including liver blood flow(LBF),liver blood volume(LBV),hepatic artery fraction,splenic blood flow and splenic blood volume were measured.HVPG was recorded during TIPS therapy.Correlation of liver perfusion with Child-Pugh score and HVPG were analyzed,and the receiver operating characteristic curve was analyzed.Based on HVPG(>12 mmHg vs≤12 mmHg),patients were divided into moderate and severe groups,and all parameters were compared.RESULTS Based on HVPG,18 patients were classified into the moderate group and 10 patients were classified into the severe group.The Child-Pugh score,HVPG,LBF and LBV were significantly higher in the moderate group compared to the severe group(all P<0.05).LBF and LBV were negatively associated with HVPG(r=-0.473,P<0.05 and r=-0.503,P<0.01,respectively),whereas splenic blood flow was positively associated with hepatic artery fraction(r=0.434,P<0.05).LBV was negatively correlated with Child-Pugh score.Child-Pugh score was not related to HVPG.Using a cutoff value of 17.85 mL/min/100 g for LBV,the sensitivity and specificity of HVPG≥12 mmHg for diagnosis were 80%and 89%,respectively.CONCLUSION LBV and LBF were negatively correlated with HVPG and Child-Pugh scores.CT perfusion imaging is a potential non-invasive quantitative predictor for PH in HBV-related liver cirrhosis. 展开更多
关键词 Hepatic venous pressure gradient Portal hypertension Computed tomography perfusion hepatitis b liver cirrhosis
下载PDF
Expression of hepatitis B virus antigen and Helicobacter pylori infection in gastric mucosa of patients with chronic liver disease 被引量:2
12
《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2004年第2期223-225,共3页
关键词 hepatitis b virus HELICObACTER PYLORI gastric MUCOSA chronic hepatitis liver cirrhosis IMMUNOHISTOCHEMICAL analysis
下载PDF
Effects of entecavir on platelet function, PTA and HBV-DNA levels in patients with hepatitis B cirrhosis 被引量:1
13
作者 Hui Wang Mu-Qian Duan +2 位作者 Feng He Jing-Jun Zhu Zhong-Jing Xia 《Journal of Hainan Medical University》 2018年第17期27-30,共4页
Objective: To explore the effect of entecavir on platelet function, PTA and HBV-DNA levels in patients with hepatitis B cirrhosis. Methods: A total of 132 patients with hepatitis B cirrhosis admitted in our hospital f... Objective: To explore the effect of entecavir on platelet function, PTA and HBV-DNA levels in patients with hepatitis B cirrhosis. Methods: A total of 132 patients with hepatitis B cirrhosis admitted in our hospital from September 2012 to May 2016 were randomly divided into control group (n=66) and observation group (n=66). The two groups were treated with routine treatment, such as reducing enzyme activity and protecting liver function. The control group was treated with lamivudine on the basis of routine treatment and the observation group was treated with entecavir. The changes of liver function, liver fibrosis, platelet index, PTA and HBV-DNA expression level in the two groups were compared. Results: Before treatment, there was no significant difference between alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), type III procollagen (PC III), laminin (LN), type IV collagen (IV-C), hyaluronidase (HA), platelet count (PLT), platelet distribution width (PDW), mean platelet volume (MPV), prothrombin activity (PTA) and hepatitis B virus RNA (HBV-DNA). After treatment, ALT, AST, TBIL, PC III, IV-C, LN and HA in both groups were significantly decreased than those before the treatment, and the decrease of PC III, IV -C, LN and HA in observation group was more significant than that of the control group;PLT and PTA in both groups were significantly increased than before treatment, while MPV, PDW and HBV-DNA were obviously decreased than before treatment, and PLT and PTA in the observation group were remarkably increased than control group, while MPV, PDW, and the control group were significantly lower than those in the control group. Conclusions: Entecavir in the treatment of hepatitis B liver cirrhosis, can reduce the HBV-DNA level, and then obviously enhance the liver function, inhibit the development of liver fibrosis, correct the abnormal platelet parameters and improve coagulation function. 展开更多
关键词 ENTECAVIR hepatitis b liver cirrhosis liver function Hepatic FIbROSIS PLATELET PTA HbV-DNA
下载PDF
Distribution of HBV DNA and HBsAg in the liver of patients with liver cirrhosis and its significance
14
作者 张晓东 王文亮 +1 位作者 刘彦仿 王伯沄 《Journal of Medical Colleges of PLA(China)》 CAS 1992年第2期136-140,共5页
Hepatitis B virus(HBV)DNA and HBsAg were detected in 51 human paraf- fin-embedded sections of liver cirrhosis by the double labelling technique of in situ hybfidiza- tion and PAP method.The results showed that the pos... Hepatitis B virus(HBV)DNA and HBsAg were detected in 51 human paraf- fin-embedded sections of liver cirrhosis by the double labelling technique of in situ hybfidiza- tion and PAP method.The results showed that the positive sections were 21(41.2%)for HBV DNA,43(84.3%)for HBsAg and 19(37.3%)for both HBV DNA and HBsAg.HBV DNA-positive grains were localized predominantly in the cytoplasm of hepatic cells or in both nucleus and cytoplasm,a few only in the nucleus or the inner side of the cell membrane.In active cirrhosis and inactive cirrhosis,the positive rates of HBV DNA were 52.8% and 13.3%,respectively,and for both HBV DNA and HBsAg,they were 47.2% and 13.3% restively.The positive rate is higher in active cirrhosis than in inactive cirrhosis(P<0.05).The results further indicated that the infection of HBV and the existence and persistent action of HBV DNA in the liver tissues are one of the important factors of the development of liver cirrhosis. 展开更多
关键词 liver cirrhosis hepatitis b virus DNA VIRAL hepatitis b surface antigens DNA probes IMMUNOHISTOCHEMISTRY human
下载PDF
Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax
15
作者 Sarah Romero Andy KH Lim +5 位作者 Gurpreet Singh Chamani Kodikara Rachel Shingaki-Wells Lynna Chen Samuel Hui Marcus Robertson 《World Journal of Gastroenterology》 SCIE CAS 2022年第35期5175-5187,共13页
BACKGROUNDHepatic hydrothorax (HH) is an uncommon and difficult-to-manage complicationof cirrhosis with limited treatment options.AIMTo define the clinical outcomes of patients presenting with HH managed withcurrent s... BACKGROUNDHepatic hydrothorax (HH) is an uncommon and difficult-to-manage complicationof cirrhosis with limited treatment options.AIMTo define the clinical outcomes of patients presenting with HH managed withcurrent standards-of-care and to identify factors associated with mortality.METHODSCirrhotic patients with HH presenting to 3 tertiary centres from 2010 to 2018 wereretrospectively identified. HH was defined as pleural effusion in the absence ofcardiopulmonary disease. The primary outcomes were overall and transplant-freesurvival at 12-mo after the index admission. Cox proportional hazards analysiswas used to determine factors associated with the primary outcomes.RESULTSOverall, 84 patients were included (mean age, 58 years) with a mean model forend-stage liver disease score of 29. Management with diuretics alone achievedlong-term resolution of HH in only 12% patients. At least one thoracocentesis wasperformed in 73.8% patients, transjugular intrahepatic portosystemic shuntinsertion in 11.9% patients and 33% patients received liver transplantation within12-mo of index admission. Overall patient survival and transplant-free survival at12 mo were 68% and 41% respectively. At multivariable analysis, current smoking [hazard ratio (HR) = 8.65, 95% confidence interval (CI): 3.43-21.9, P < 0.001) and acute kidneyinjury (AKI) (HR = 2.91, 95%CI: 1.21-6.97, P = 0.017) were associated with a significantly increasedrisk of mortality.CONCLUSIONCirrhotic patients with HH are a challenging population with a poor 12-mo survival despitecurrent treatments. Current smoking and episodes of AKI are potential modifiable factors affectingsurvival. HH is often refractory of diuretic therapy and transplant assessment should beconsidered in all cases. 展开更多
关键词 cirrhosis Portal hypertension Hepatic hydrothorax ascites liver transplantation
下载PDF
Clinical Characteristics in Patients with Liver Cirrhosis Induced by HBV Infection and Combined with Mild Alcohol Intake
16
作者 Ha-lida Xiaerfuhazi Hai-lin Ma +3 位作者 Xiu-jiang Shi Xiao-tang Fan Xi-ernayi Abuduheilili Fang-ping He 《国际感染病学(电子版)》 CAS 2014年第3期97-102,共6页
Objective To investigate the differences of clinical and biochemical characteristics between patients with liver cirrhosis induced by HBV infection combined with and without mild alcohol intake.Methods Data of patient... Objective To investigate the differences of clinical and biochemical characteristics between patients with liver cirrhosis induced by HBV infection combined with and without mild alcohol intake.Methods Data of patients with liver cirrhosis who were hospitalized in the First Hospital Affiliated to Xinjiang Medical University were retrospectively analyzed. Patients were divided into three groups: patients with liver cirrhosis induced by HBV infection and combined with mild alcohol intake, patients with HBV-related cirrhosis, and patients with alcohol-related cirrhosis. Biochemical detections including liver function, fasting lipid profiles, lipoprotein, kidney function, glucose, uric acid and regular blood tests were carried out and results were compared among three groups. Data were analyzed through STATA software and co-variant analysis. Results Total of 2 350 patients with liver cirrhosis were included, 732 patients had cirrhosis induced by HBV infection combined with mild alcohol intake, 1 316 patients had HBV-related liver cirrhosis, 302 patients had alcohol-related cirrhosis. The highest mean level of white cell count, mean corpuscular volume, γ-glutamyltranspeptidase and uric acid were observed in HBV infection combined with mild alcohol intake group. Multivariate regression analysis revealed that HBV infection, excessive alcohol intake, male and age were risk factors for hepatocellular carcinoma(HCC) in patients with liver cirrhosis. Conclusions HBV infection combined with mild alcoholic-related liver cirrhosis group showed the highest oxidative stress compared with alcoholic liver cirrhosis group, which suggested that mild alcohol intake may increase the incidence of liver cirrhosis in HBV infected patients and may not increase the incidence of HCC. 展开更多
关键词 liver cirrhosis Oxidative stress hepatitis b virus Mild alcohol biochemical characteristics
下载PDF
Analysis of the Clinical Value of Baogan Lishui Decoction and Conventional Western Medicine in Treating Hepatitis B Cirrhosis Refractory Ascites
17
作者 Lin Huai De 《Journal of Clinical and Nursing Research》 2018年第4期5-7,共3页
The objective of this study was to investigate the clinical effect of combination treatment of Chinese medicine Baogan Lishui decoction and western medicine on hepatitis B(Hep B)cirrhosis-related refractory ascites.Th... The objective of this study was to investigate the clinical effect of combination treatment of Chinese medicine Baogan Lishui decoction and western medicine on hepatitis B(Hep B)cirrhosis-related refractory ascites.The control group was given conventional western medicine therapy while the observation group was given same conventional western medicine therapy with additional of Chinese medicine Baogan Lishui decoction.The total effective of clinical treatment on Hep B cirrhosis-related refractory ascites in observation group was higher than that of the control group which was 88.89%compared to 71.11%,respectively,and it was significant different(P<0.05).The combination treatment of Chinese medicine Baogan Lishui decoction and conventional western medicine can significantly increase the treatment effect on Hep B cirrhosis refractory ascites,and thus increases the quality and safety of life. 展开更多
关键词 hepatitis b cirrhosis REFRACTORY ascites baogan Lishui DECOCTION CONVENTIONAL western medicine combination treatment effect
下载PDF
Effect of the reduced glutathione antioxidation combined with conventional antiviral drugs on hepatic fibrosis in patient with hepatitis b cirrhosis
18
作者 Sheng-Shui Liu 《Journal of Hainan Medical University》 2017年第16期21-24,共4页
Objective: To study the effect of the reduced glutathione antioxidation combined with conventional antiviral drugs on hepatic fibrosis in patient with liver cirrhosis. Methods: A total of 300 patients with hepatitis b... Objective: To study the effect of the reduced glutathione antioxidation combined with conventional antiviral drugs on hepatic fibrosis in patient with liver cirrhosis. Methods: A total of 300 patients with hepatitis b cirrhosis who were treated in Shangluo Central Hospital between August 2012 and August 2016 were collected and divided into the control group (n=159) who received conventional antiviral therapy and the observation group (n=141) who received reduced glutathione antioxidation combined with conventional antiviral drug therapy. The differences in serum levels of fibrosis indicators, inflammatory factors and oxidative stress indexes were compared between the two groups of patients before and after treatment. Results: Before treatment, differences in serum levels of fibrosis indexes, inflammatory factors and oxidative stress indexes were not statistically significant between two groups of patients. After treatment, serum HA, Ⅳ-C, LN, PCⅢ, PCT, IL-6, IL-22, IL-31, TNF-α and MDA levels of both groups of patients were lower than those before treatment while GSH-Px and T-SOD levels were higher than those before treatment, and serum HA, Ⅳ-C, LN, PCⅢ, PCT, IL-6, IL-22, IL-31, TNF-α and MDA levels of observation group after treatment were lower than those of control group while GSH-Px and T-SOD levels were higher than those of control group. Conclusion: Reduced glutathione antioxidation combined with conventional antiviral drugs can effectively inhibit the fibrosis process in patients with hepatitis b cirrhosis, which is because that it reduces the degree of inflammation and oxidative stress reaction. 展开更多
关键词 hepatitis b cirrhosis Reduced GLUTATHIONE liver FIbROSIS
下载PDF
Effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis
19
作者 Xue-Wei Zhang Wei Shi +2 位作者 Xiao-Fei Yin Li-Min Chen Da-Rong Yuan 《Journal of Hainan Medical University》 2017年第20期39-42,共4页
Objective: To study the effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis. Methods: Patients who were diagn... Objective: To study the effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis. Methods: Patients who were diagnosed with chronic hepatitis b complicated by compensated liver cirrhosis in our hospital between March 2015 and January 2017 were selected and randomly divided into two groups, observation group received Thymosin Injection combined with entecavir therapy, and control group received entecavir therapy. The viral load, liver function injury indexes, liver fibrosis indexes, immune cytokines and immune cell apoptosis molecules were measured 24 weeks after treatment. Results: 24 weeks after treatment, HBV-DNA copy number in peripheral blood as well as ALT, AST, TBIL, HA, PC-III, LN, C-IV, IL-4, IL-10, TGF-β1, IL-17 and IL-22 levels in serum of observation group was significantly lower than those of control group, and peripheral blood FAS, CYCS, CASP8, CASP9 and CASP3 mRNA expression were significantly lower than those of control group. Conclusion:Thymosin Injection combined with entecavir therapy can reduce viral load, improve liver function, inhibit liver fibrosis and regulate immune function in patients with compensated liver cirrhosis. 展开更多
关键词 Chronic hepatitis b liver cirrhosis Thymopeptides FIbROSIS Immune response
下载PDF
Observation on the effect of adefovir dipivoxil in combined with lamivudine in the treatment of hepatitis B cirrhosis
20
作者 Li Cui 《Journal of Hainan Medical University》 2017年第5期13-16,共4页
Objective:To explore the effect of adefovir dipivoxil in combined with lamivudine on the liver function in patients with hepatitis B cirrhosis and the antiviral efficacy.Methods:A total of 156 patients with hepatitis ... Objective:To explore the effect of adefovir dipivoxil in combined with lamivudine on the liver function in patients with hepatitis B cirrhosis and the antiviral efficacy.Methods:A total of 156 patients with hepatitis B cirrhosis who were admitted in our hospital were included in the study and randomized into the treatment group and the control group with 78 cases in each group. The patients in the treatment group were given adefovir dipivoxil in combined with lamivudine, while the patients in the control group were given entecavir. After 12-month treatment, the efficacy was evaluated. The liver function, serum virology indicators, and AFP before and after treatment in the two groups were compared. The adverse reactions during the treatment process were recorded.Results: The serum GTP, ALT, AST, and TBIL levels after treatment in the two groups were significantly reduced when compared with before treatment (P<0.05);moreover, ALT and TBIL levels in the treatment group were significantly lower than those in the control group (P<0.05). HBeAg, HBV-DNA, and AFP levels after treatment in the two groups were significantly reduced when compared with before treatment (P<0.05), HBeAg and AFP levels in the treatment group were significantly lower than those in the control group (P<0.05), and the comparison of HBV-DNA between the two groups was not statistically significant (P>0.05). ALT normalization rate and HBeAg negative conversion rate after treatment in the treatment group were significantly higher than those in the control group (P<0.05). The comparison of HBV-DNA negative conversion rate and HBeAg conversion rate between the two groups was not statistically significant (P>0.05). No obvious drug adverse reactions and liver function damage occurred during the treatment process in the two groups. Conclusions:Adefovir dipivoxil in combined with lamivudine can significantly improve the liver function and serum virology indicators in patients with hepatitis B cirrhosis, with antiviral efficacy significantly superior to that by entecavir. 展开更多
关键词 hepatitis b cirrhosis ADEFOVIR dipivoxil LAMIVUDINE liver function ANTIVIRAL EFFICACY
下载PDF
上一页 1 2 130 下一页 到第
使用帮助 返回顶部